Not available
Quote | Editas Medicine Inc. (NASDAQ:EDIT)
Last: | $4.66 |
---|---|
Change Percent: | 0.0% |
Open: | $4.6 |
Close: | $4.66 |
High: | $4.7399 |
Low: | $4.56 |
Volume: | 988,041 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
News | Editas Medicine Inc. (NASDAQ:EDIT)
2024-06-25 08:00:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Gene-editing stocks has been gaining substantial attention, as the industry holds the potential to revolutionize medicine. From curing genetic disorders to enhancing agricultural productivity, ...
All patients treated in the RUBY trial are free of vaso-occlusive events post- renizgamglogene autogedtemcel (reni-cel) infusion Patients had early normalization of total hemoglobin with a mean within the normal range at >14 g/dL and rapid and sustained improvements in fetal ...
Message Board Posts | Editas Medicine Inc. (NASDAQ:EDIT)
Subject | By | Source | When |
---|---|---|---|
Could be upcoming https://annualmeeting.asgct.org/program/agenda-details?agendaI | jondoeuk | investorshub | 04/13/2023 10:21:36 PM |
Does this have any FDA approvals? | jondoeuk | investorshub | 03/19/2023 7:39:22 PM |
Does this have any FDA approvals? Will Precision | rtrstock | investorshub | 03/07/2023 6:59:07 PM |
PR https://www.globenewswire.com/news-release/2022/05/18/2445810/0/en/Editas-Med | jondoeuk | investorshub | 05/19/2022 5:39:30 PM |
1106: $EDIT-202, a Multiplexed CRISPR-Cas12a Gene-Edited iPSC-Derived NK | jondoeuk | investorshub | 05/02/2022 9:43:49 PM |
News, Short Squeeze, Breakout and More Instantly...
All patients treated in the RUBY trial are free of vaso-occlusive events post- renizgamglogene autogedtemcel (reni-cel) infusion Patients had early normalization of total hemoglobin with a mean within the normal range at >14 g/dL and rapid and sustained improvements in fetal ...
All patients treated in the EdiTHAL trial maintained hemoglobin levels above the transfusion threshold and are transfusion-free post- renizgamglogene autogedtemcel (reni-cel) infusion Reni-cel was well-tolerated and demonstrated a safety profile consistent with myeloablative con...